基于索磷布韦的直接抗病毒药物治疗成年慢性丙型肝炎病毒感染非1型患者安全性研究  

The Real-world Efficacy and Safety Study of a Direct Antiviral Drug Regimen Based on Sofosbuvir in the Treatment of Adult Non-type 1 Patients with Chronic HCV Infection in China

作　　者：刘金峰 梁敏锋 骆海飞 LIU Jin-feng;LIANG Min-feng;LUO Hai-fei(Department of Infection,Foshan First People’s Hospital,Foshan Hospital Affiliated to Sun Yat-sen University,Foshan,Guangdong,528000,China)

机构地区：[1]佛山市第一人民医院(中山大学附属佛山医院)感染科,广东佛山528000

出　　处：《黑龙江医学》2022年第4期402-404,共3页Heilongjiang Medical Journal

摘　　要：目的:了解基于索磷布韦的直接抗病毒药物(DAAs)方案治疗中国成年慢性丙型肝炎病毒(HCV)感染非1型患者的真实世界疗效及安全性。方法:选取2018年4月—2020年1月佛山市第一人民医院门诊就诊并使用基于索磷布韦的DAAs方案联合或不联合利巴韦林治疗12周的40例非1型慢性HCV感染者的临床资料,其中丙型肝炎后肝硬化7例,慢性丙型肝炎33例。检测患者基线、治疗2周或4周、疗程结束、随访12周的丙型肝炎病毒核糖酸(HCVRNA)、肝功能、血常规、肾功能、凝血功能、腹部彩超及肝脏弹性硬度值,记录治疗过程中的不良事件和实验室异常。结果:与治疗前对比,治疗2周慢性丙型肝炎和丙型肝炎后肝硬化患者的天门冬氨酸氨基转移酶(AST)、谷丙转氨酶(ALT)、总胆红素(TBIL)水平明显下降,治疗4周、12周以及停药12周的AST、ALT、TBIL水平较治疗前均有所下降;2a、3a、3b、6a慢性丙型肝炎以及3a、3b、6a丙型肝炎肝硬化患者的病毒学应答(SVR)12均为100.00%。结论:基于索磷布韦的DAAs方案治疗中国成年慢性HCV感染非1型患者疗效显著,治疗阶段无明显不良反应。Objective:To investigate the efficacy and safety of direct antiviral drug(DAAs)regimen based on Sofosbuvir in the treatment of non-type 1 chronic HCV infection in Chinese adults.Methods:From April 2018 to January 2020,40 patients with non-type 1 chronic hepatitis C virus(HCV)infection who were treated with sofosbuvir-based DAAs with or without ribavirin for 12 weeks in the hospital from April 2018 to January 2020 were collected,including 7 cases of post-hepatitis C cirrhosis and 33 cases of chronic hepatitis C.HCVRNA,liver function,blood routine,renal function,blood coagulation function,abdominal color Doppler ultrasound,liver elasticity hardness value of patients at baseline,2 or 4 weeks of treatment,end of treatment,and 12 weeks of follow-up were tested,and adverse events and the abnormality in the laboratory during treatment were recorded.The comparison of measurement data between two groups was performed by t test,and the comparison between multiple groups was performed by analysis of variance.Results:Compared with before treatment,the levels of AST,ALT,TBIL in patients with chronic hepatitis C and posthepatitis C cirrhosis after 2 weeks of treatment significantly decreased.The levels of AST,ALT and TBIL after 4 weeks of treatment,12 weeks of treatment and 12 weeks of withdrawal all decreased compared with those before treatment.The SVR12 of patients with 2a,3a,3b,6a chronic hepatitis C and 3a,3b,6a hepatitis C cirrhosis were all 100.00%.Conclusion:The DAAs regimen based on Sofosbuvir is effective in the treatment of non-type 1 chronic HCV infection in Chinese adults,with no significant adverse reactions in the treatment stage.

关 键 词：索磷布韦 直接抗病毒药物 慢性丙型肝炎 基因分型 

分 类 号：R512.63[医药卫生—内科学]